NRXP stock news · NRX Pharmaceuticals
Get alerts for NRXP
Follow NRX Pharmaceuticals (NRXP) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for NRXP12 health care stocks are changing in price before the market opens, with NRX Pharmaceuticals going up and Acumen Pharmaceuticals dropping.
NeutralNRX Pharmaceuticals shares rose about 12% before Friday's trading, but the story reports no new company news. This leaves its business outlook unchanged.
NRx Pharmaceuticals' stock rose more than 26% after hours because they announced a call about a key step in their ketamine program.
NeutralNRx Pharmaceuticals plans to discuss a regulatory milestone for its ketamine program, but has not revealed what changed. The missing details leave its outlook unchanged for now.
NRX Pharmaceuticals says its annual meeting for stockholders will be on December 17, 2026.
NeutralNRX set its annual meeting for December 17 and revised shareholder proposal deadlines. These are meeting procedures, not business news, so the filing does not change the company's outlook.
NRX Pharmaceuticals has signed an important deal with DARPA for a clinical trial worth about $11.2 million.
Good for NRXPNRX Pharmaceuticals won a DARPA contract to run a depression study. The award supports its work, though only part of the funding is committed so far.
Q2 2026 results delivered by NRX Pharmaceuticals: Complete earnings call transcript available.
NeutralNRX Pharmaceuticals' Q2 2026 results show a reduced net loss and strategic advancements in drug development, including FDA reviews and an acquisition that could enhance their treatment portfolio. This positions the company favorably for future growth and potential partnerships.